US20170100319A1 - Compositions for Reducing Hair Loss and/or Increasing Hair Regrowth - Google Patents

Compositions for Reducing Hair Loss and/or Increasing Hair Regrowth Download PDF

Info

Publication number
US20170100319A1
US20170100319A1 US15/292,819 US201615292819A US2017100319A1 US 20170100319 A1 US20170100319 A1 US 20170100319A1 US 201615292819 A US201615292819 A US 201615292819A US 2017100319 A1 US2017100319 A1 US 2017100319A1
Authority
US
United States
Prior art keywords
composition
month
hair
finasteride
minoxidil
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US15/292,819
Inventor
Houfar Sekhavat
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Triple Hair Inc
Original Assignee
Triple Hair Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US201462002397P priority Critical
Priority to CA2903734 priority
Priority to PCT/CA2015/000327 priority patent/WO2015176161A1/en
Priority to CA2903734A priority patent/CA2903734C/en
Priority to US201614917501A priority
Application filed by Triple Hair Inc filed Critical Triple Hair Inc
Priority to US15/292,819 priority patent/US20170100319A1/en
Assigned to TRIPLE HAIR INC. reassignment TRIPLE HAIR INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: SEKHAVAT, Houfar
Publication of US20170100319A1 publication Critical patent/US20170100319A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K8/00Cosmetics or similar toilet preparations
    • A61K8/18Cosmetics or similar toilet preparations characterised by the composition
    • A61K8/30Cosmetics or similar toilet preparations characterised by the composition containing organic compounds
    • A61K8/63Steroids; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/557Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K8/00Cosmetics or similar toilet preparations
    • A61K8/02Cosmetics or similar toilet preparations characterised by special physical form
    • A61K8/0204Specific forms not provided for by any of groups A61K8/0208 - A61K8/14
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K8/00Cosmetics or similar toilet preparations
    • A61K8/02Cosmetics or similar toilet preparations characterised by special physical form
    • A61K8/04Dispersions; Emulsions
    • A61K8/046Aerosols; Foams
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K8/00Cosmetics or similar toilet preparations
    • A61K8/18Cosmetics or similar toilet preparations characterised by the composition
    • A61K8/30Cosmetics or similar toilet preparations characterised by the composition containing organic compounds
    • A61K8/33Cosmetics or similar toilet preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36Carboxylic acids; Salts or anhydrides thereof
    • A61K8/361Carboxylic acids having more than seven carbon atoms in an unbroken chain; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K8/00Cosmetics or similar toilet preparations
    • A61K8/18Cosmetics or similar toilet preparations characterised by the composition
    • A61K8/30Cosmetics or similar toilet preparations characterised by the composition containing organic compounds
    • A61K8/33Cosmetics or similar toilet preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/37Esters of carboxylic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K8/00Cosmetics or similar toilet preparations
    • A61K8/18Cosmetics or similar toilet preparations characterised by the composition
    • A61K8/30Cosmetics or similar toilet preparations characterised by the composition containing organic compounds
    • A61K8/49Cosmetics or similar toilet preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494Cosmetics or similar toilet preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A61K8/4953Cosmetics or similar toilet preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom containing pyrimidine ring derivatives, e.g. minoxidil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/14Drugs for dermatological disorders for baldness or alopecia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILET PREPARATIONS
    • A61Q7/00Preparations for affecting hair growth
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K2800/00Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/59Mixtures
    • A61K2800/592Mixtures of compounds complementing their respective functions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions

Abstract

The invention relates to a composition comprising 2% to 5% minoxidil, 0.01% to 15% finasteride and 0.01% to 15% of a prostaglandin analogue. In one embodiment, the prostaglandin analogue is latanoprost. In a preferred embodiment, the composition comprises 5% minoxidil, 0.1% finasteride and 0.03% latanoprost. The invention also relates to the use of the said composition to reduce hair loss and/or increase regrowth of hair in a human subject.

Description

    CROSS-REFERENCE TO RELATED APPLICATIONS
  • This Non-Provisional Patent Application is a continuation of and claims priority under 35 U.S.C. §120 to U.S. Non-Provisional patent application Ser. No. 14/917,501, filed Mar. 8, 2016, which claims priority under 35 U.S.C. §120 and §§119(a)-(d) to and is a national phase patent application of International Patent Application No. PCT/CA2015/000327, filed May 22, 2015, entering the U.S. under 35 U.S.C. §371 and Published in English as WO2015/176161 A1, which International Application claims the benefit under 35 U.S.C. §119(e) of U.S. Provisional Patent Application No. 62/002,397, filed May 23, 2014 and U.S. Non-Provisional patent application Ser. No. 14/917,501, filed Mar. 8, 2016, further claims priority under 35 U.S.C. 119(a)-(d) to Canadian Patent Application No.2,903,734, filed May 22, 2015. The disclosure of each of the above-noted patent applications is incorporated herein by reference in its entirety.
  • BACKGROUND OF THE INVENTION
  • Field of the Invention
  • The inventor has discovered that a composition comprising minoxidil, finasteride and a prostaglandin analogue shows improved properties in terms of reducing hair loss and increasing hair regrowth when compared to conventional therapies, such as the topical application of a solution of 5% minoxidil.
  • Description of Related Art
  • Androgenetic alopecia (AGA) is hair loss (at scalp level) caused by the thinning of hair follicles. It is very common in men between the age of 19 and 70 years. Notably, more than 50% of Caucasian men in their fifties are affected by it. Women's hair loss mostly becomes an issue after menopause.
  • Individuals affected by androgenetic alopecia (AGA) show a diminution of their self-esteem that can effect negatively many facets of their lives. The inventor has discovered that a composition for topical administration comprising minoxidil, finasteride and a prostaglandin analogue is effective in reducing hair loss and increasing hair regrowth.
  • There are several hair loss prevention products on the market. By way of example, minoxidil has been in use since the 1990s in topical form at 2% concentration (without prescription) and at 3% and 5% concentration (with prescription). While studies demonstrate the efficiency of 5% minoxidil over the 2% concentration, minoxidil is less than 40% effective in promoting regrowth of the hair. Minoxidil is considered the topical gold standard available for treatment of hair loss.
  • Another hair loss prevention product is finasteride. It is administered orally usually at a dosage of 1 mg/day. There are a number of side effects associated with the administration of finasteride including lowered libido, impotence, ejaculation disorders, allergic reactions, testicular pain, male infertility, male breast cancer and depression. At higher concentrations (5 mg), finasteride can cause benign prostate hyperplasia.
  • Latanoprost, a PGF2 a prostaglandin analog, is widely used in ophthalmology to treat open angle glaucoma and ocular hypertension. One of its side effects has been an augmentation of periocular hirsuteness, which includes a surge in the thickness, length and pigmentation of eyelashes which is to be distinguished from hair growth. Some of its other adverse effects are erythema, folliculitis, sensation of burning and erysipelas. A latanoprost ophthalmic solution has a concentration of 0.005%. It should be noted that scalp hair follicles and eyelash follicles are not identical and one cannot simply extrapolate from a drug effect on one type of hair to another.
  • BRIEF SUMMARY OF THE INVENTION
  • The inventor has discovered that a composition comprising minoxidil, finasteride and a prostaglandin analogue for topical application to the scalp reduces hair loss and increases hair regrowth. Such a composition shows superior improvements to those seen for each of the components of the composition taken individually and the results obtained to date suggest that the improvements may be superior to those of the sum of the said components.
  • The invention relates to a composition comprising 2% to 5% minoxidil, 0.01% to 15% finasteride and 0.01% to 15% of a prostaglandin analogue. In one embodiment, the prostaglandin analogue is latanoprost. In another embodiment, the composition comprises 5% minoxidil, 0.1% finasteride and 0.03% latanoprost. The invention also relates to the use of a composition comprising 2% to 5% minoxidil, 0.01% to 15% finasteride and 0.01% to 15% of a prostaglandin analogue to reduce hair loss and/or increase regrowth of hair in a human subject.
  • BRIEF DESCRIPTION OF THE SEVERAL VIEWS OF THE DRAWINGS
  • FIGS. 1 A to 1L are a series of photographs showing the scalp of participant 1 prior to treatment and at intervals throughout the course of a six month treatment with a composition of the invention. FIGS. 1A and 1B show the scalp before treatment on the first day of month 1, FIGS. 1C and 1D show the scalp on month 2, FIGS. 1E and 1F on month 3, FIGS. 1G and 1H on month 4, FIGS. II and 1 J on month 5 and FIGS. 1K and 1L on month 6;
  • FIGS. 2A to 2L are a series of photographs showing the scalp of participant 2 prior to treatment and at intervals throughout the course of a six month treatment with a composition of the invention. FIGS. 2 A and 2B show the scalp before treatment on the first day of month 1, FIGS. 2C and 2D show the scalp on month 2, FIGS. 2E and 2F on month 3, FIGS. 2G and 2H on month 4, FIGS. 21 and 2J on month 5 and FIGS. 2K and 2L on month 6;
  • FIGS. 3A to 3L are a series of photographs showing the scalp of participant 3 prior to treatment and at intervals throughout the course of a six month treatment with a composition of the invention. FIGS. 3 A and 3B show the scalp before treatment on the first day of month 1, FIGS. 3C and 3D show the scalp on month 2, FIGS. 3E and 3F on month 3, FIGS. 3G and 3H on month 4, FIGS. 31 and 3J on month 5 and FIGS. 3K and 3L on month 6;
  • FIGS. 4A to 4L are a series of photographs showing the scalp of participant 4 prior to treatment and at intervals throughout the course of a six month treatment with a solution of 5% minoxidil only. FIGS. 4 A and 4B show the scalp before treatment on the first day of month 1, FIGS. 4C and 4D show the scalp on month 2, FIGS. 4E and 4F on month 3, FIGS. 4G and 4H on month 4, FIGS. 41 and 4J on month 5 and FIGS. 4K and 4L on month 6;
  • FIGS. 5A to 5L are a series of photographs showing the scalp of participant 5 prior to treatment and at intervals throughout the course of a six month treatment with a solution of 0.1% finasteride only. FIGS. 5 A and 5B show the scalp before treatment on the first day of month 1, FIGS. 5C and 5D show the scalp on month 2, FIGS. 5E and 5F on month 3, FIGS. 5G and 5H on month 4, FIGS. 51 and 5J on month 5 and FIGS. 5K and 5L on month 6;
  • FIGS. 6A to 6L are a series of photographs showing the scalp of participant 6 prior to treatment and at intervals throughout the course of a six month treatment with a solution of 0.1% finasteride only. FIGS. 6A and 6B show the scalp before treatment on the first day of month 1, FIGS. 6C and 6D show the scalp on month 2, FIGS. 6E and 6F on month 3, FIGS. 6G and 6H on month 4, FIGS. 61 and 6J on month 5 and FIGS. 6K and 6L on month 6;
  • FIGS. 7A to 7G are a series of photographs showing the scalp of participant 7 prior to treatment and at intervals throughout the course of a six month treatment with a solution of 0.1% finasteride only. FIGS. 7 A and 7B show the scalp before treatment on the first day of month 1, FIG. 7C shows the scalp on month 2, FIG. 7D on month 3, FIG. 7E on month 4, FIG. 7F on month 5 and FIG. 7G on month 6;
  • FIGS. 8A to 8L are a series of photographs showing the scalp of participant 8 prior to treatment and at intervals throughout the course of a six month treatment with a solution of 0.1% finasteride only. FIGS. 8 A and 8B show the scalp before treatment on the first day of month 1, FIGS. 8C and 8D show the scalp on month 2, FIGS. 8E and 8F on month 3, FIGS. 8G and 8H on month 4, FIGS. 81 and 8J on month 5 and FIGS. 8K and 8L on month 6;
  • FIGS. 9A to 9L are a series of photographs showing the scalp of participant 9 prior to treatment and at intervals throughout the course of a six month treatment with a solution of 0.03%>latanoprost only. FIGS. 9A and 9B show the scalp before treatment on the first day of month 1, FIGS. 9C and 9D show the scalp on month 2, FIGS. 9E and 9F on month 3, FIGS. 9G and 9H on month 4, FIGS. 91 and 9 J on month 5 and FIGS. 9K and 9L on month 6;
  • FIGS. 10A to 10L are a series of photographs showing the scalp of participant 10 prior to treatment and at intervals throughout the course of a six month treatment with a solution of 0.03%) latanoprost only. FIGS. 10A and 10B show the scalp before treatment on the first day of month 1, FIGS. 10C and 10D show the scalp on month 2, FIGS. 10E and 10F on month 3, FIGS. 10G and 10H on month 4, FIGS. 101 and 10J on month 5 and FIGS. 10K and 10L on month 6.
  • FIGS. 6A to 6L are a series of photographs showing the scalp of participant 6 prior to treatment and at intervals throughout the course of a six month treatment with a solution of 0.1% finasteride only;
  • FIGS. 7A to 7G are a series of photographs showing the scalp of participant 7 prior to treatment and at intervals throughout the course of a six month treatment with a solution of 0.1% finasteride only;
  • FIGS. 8A to 8L are a series of photographs showing the scalp of participant 8 prior to treatment and at intervals throughout the course of a six month treatment with a solution of 0.1% finasteride only;
  • FIGS. 9A to 9L are a series of photographs showing the scalp of participant 9 prior to treatment and at intervals throughout the course of a six month treatment with a solution of 0.03% latanoprost only; and
  • FIGS. 10A to 10L are a series of photographs showing the scalp of participant 10 prior to treatment and at intervals throughout the course of a six month treatment with a solution of 0.03% latanoprost only.
  • DETAILED DESCRIPTION OF THE INVENTION
  • The invention relates to a composition comprising minoxidil, finasteride and a prostaglandin analog which shows improved properties for the reduction of hair loss and for the increase of hair regrowth in human subjects, when compared to minoxidil, finasteride and latanoprost taken alone.
  • Minoxidil or (6-(1-pipedidinyl)-2,4-pyrimidinediamine 3-oxide) has the following structural formula:
  • Figure US20170100319A1-20170413-C00001
  • Minoxidil is a crystalline solid which has a solubility in mg/ml of 75 in propylene glycol, of 44 in methanol, of 29 in ethanol, of 6.7 in 2-propanol, of 6.5 in DMSO, of 2.2 in water, of 0.5 in chloroform, and of <0.5 in acetone. Minoxidil has a pKa of 4.61. Finasteride or ((5α,17β)-N-(1,1-Dimethylethyl)-3-oxo-4-azaandrost-1-ene-17-carboxamide) has the following structural formula:
  • Figure US20170100319A1-20170413-C00002
  • Finasteride is conventionally administered orally at a daily dose of 1 mg.
  • Finasteride is an anhydrous crystalline solid. Finasteride is freely soluble in chloroform, DMSO, ethanol, methanol, n-propanol; sparingly soluble in propylene glycol, polyethylene glycol 400; and very slightly soluble in 0.1N HCl and 0.1N NaOH. Finasteride is not soluble in water.
  • Latanoprost or ((5Z)-7-[(1R,2R,3R,5SO-3,5-Dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]-5-heptenoic acid 1 -methylethyl ester) has the following structural formula:
  • Figure US20170100319A1-20170413-C00003
  • Latanoprost is an oil. Latanoprost is very soluble in acetonitrile; freely soluble in acetone, ethanol, ethyl acetate, isopropanol, methanol and octanol. It is practically insoluble in water.
  • Prostaglandins regulate a number of physiological functions. It has been found that most hair cell types are endowed with prostaglandin metabolism machinery and are thus able to produce PGE2 and/or PGF2a. The epithelial part of the hair bulb is the main source of prostaglandin synthesis and interconversion. From Colombe et al. (Prostaglandin Metabolism in Human Hair Follicle, Exp. Dermatol. 2007 September, 16 (9): 762 to 769) and as minoxidil has also been found to enhance prostaglandin endoperoxide synthase-1 (PGHS-1) activity, this suggests that prostaglandins are involved in hair growth and differentiation control and that there is a link between prostaglandin synthesis and hair growth. Minoxidil has been demonstrated to be a potent activator of purified PGHS-1 by assaying oxygen consumption in prostaglandin PGE2 production suggesting that the mechanism beyond the hair-growth stimulating effect of minoxidil is stimulation of PGE2 synthesis (Michelet et al., Activation of Cytoprotected Prostaglandin Synthase-1 by Minoxidil as a Possible Explanation for Its Hair Growth-Stimulating Effect, J. Invest. Dermatol. 1997: 108: 205-209). This has been confirmed by the role of PGHS-2 in the control of hair cycle (Muller-Decker et al., Expression of Cyclo-Oxygenase Isozymes During Morphogenesis and Cycling of Telage Hair Follicles in Mouse Skin, J. Invest. Dermatol. 2003: 121 : 661-668). It has been shown that the human hair follicle can sustain a complete PGE2 and PGF2a metabolism. Human hair follicle express (i) mPGES-1, mPGES-2 and cPGES which catalyse PGE2 synthesis from PGH2, (ii) AK1C3/PGFS which converts PGH2 into PGF2a and (iii) CDR1 and AKR1C1 aldoketoreductase, which could control PGE2/PGF2a interconversion. As such, it has been shown that human hair follicles appear fully enzymatically equipped to self-process prostaglandin synthesis and metabolism, meaning PGE2 and PGF2a could be produced and inter-converted by hair follicles. While the composition tested comprised latanoprost, a PGF2a prostaglandin analogue, it is surmised that other prostaglandin analogues can also be used given the role played by prostaglandin in hair growth and differentiation. By way of example, other suitable prostaglandin analogues include travoprost, bimatoprost, tafluprost and unoprostone.
  • The composition of the invention comprises 2% to 5% minoxidil, 0.01% to 15% finasteride and 0.01% to 15%) of a prostaglandin analogue. In a preferred embodiment, the composition comprises 2% to 5% minoxidil, 0.01% to 5% finasteride and 0.01% to 5% of a prostaglandin analogue. In a more preferred embodiment, the composition comprises 5% minoxidil, 0.5% finasteride and 0.1% of a prostaglandin analogue. In a yet other preferred embodiment, the prostaglandin analogue is latanoprost, travoprost, bimatoprost, tafluprost or unoprostone. In a further preferred embodiment, the prostaglandin analogue is latanoprost. In an even more preferred embodiment, the composition comprises 5% minoxidil, 0.1% finasteride and 0.03% latanoprost as set out in Table 1 below.
  • In order to demonstrate the improved properties of a composition suitable for topical application comprising minoxidil, finasteride and a prostaglandin analogue, latanoprost, the composition was compared to compositions comprising 5% minoxidil only, 0.1% finasteride only and 0.03% latanoprost only. The various compositions were prepared as follows.
  • EXAMPLE 1 Preparation of Composition Comprising Finasteride. Latanoprost and Minoxidil
  • In order to prepare the composition, latanoprost was diluted to obtain a concentration of 10,000 mcg/ml of solute on in absolute ethyl alcohol, and prepared as a stock solution and kept in a freezer to enhance stability (−20° C.). Absolute ethyl alcohol was mixed with propylene glycol and heated to 55°-65° C. Minoxidil powder was then added to the alcohol/propylene glycol mixture. In a containment hood, finasteride was added to the solution and stirred until dissolved. The preparation was cooled to room temperature. Ethoxy diglycol and latanoprost were added to the cooled solution and stirred well, until in solution. The final solution was brought to volume with absolute ethyl alcohol.
  • The amounts used are set out in Table 1 below:
  • TABLE 1
    Component Function Quantity per unit %
    Propylene glycol Solvent 30 ml 50
    Minoxidil USP Active 3 g 5
    Finasteride USP Active 0.06 g 0.1
    Ethoxy diglycol Solvent 3 ml 5
    reagent
    Latanoprost Active 1.8 ml 0.03
    (10,000 mcg/ml)
    Absolute ethyl Solvent QS 60 ml 39.87
    alcohol
    Total 60 ml 100%
  • Various modifications for the preparation of the composition of the invention will be apparent to the skilled worker. Furthermore, other pharmaceutically acceptable additives such as suspending agents, emulsifying agents, non-aqueous vehicles and preservatives can be added. The techniques for the preparation of these compositions are well known in the art and reference may be had to Remington's Pharmaceutical Sciences, 18th edition, Mack Publishing Co., Easton, Pa., USA 18042.
  • EXAMPLE 2 Preparation of Composition Comprising Minoxidil
  • A composition comprising 5% minoxidil was prepared. Absolute ethyl alcohol was mixed with propylene glycol and heated to 55° to 65° C. The minoxidil powder was added to the alcohol/propylene glycol mixture. Ethoxy diglycol was added and the solution was stirred. The final solution was brought to volume with absolute ethyl alcohol to obtain a solution comprising 5% minoxidil.
  • EXAMPLE 3
  • Preparation of Composition Comprising Finasteride
  • A composition comprising 0.1% finasteride was also prepared. Absolute ethyl alcohol was mixed with propylene glycol. Finasteride was added to the alcohol/propylene glycol mixture to obtain a solution having a concentration of 0.1% finasteride. Absolute ethyl alcohol also serves the function of preservative.
  • EXAMPLE 4
  • Preparation of Composition Comprising Latanoprost
  • A solution comprising 0.03% latanoprost was prepared. Absolute ethyl alcohol was mixed with propylene glycol. The latanoprost was added to the alcohol/propylene glycol mixture. The final solution was brought to volume with absolute ethyl alcohol in order to obtain a solution having a concentration of 0.03% latanoprost. The absolute ethyl alcohol also serves the function of preservative in this composition.
  • EXAMPLE 5
  • Treatment of Participants With Composition of Invention and Comparators—Analysis and Measurements
  • For each participant, the distance between the base of the nose and the middle of the hair crown was noted, as well as the distance separating the most distal part of the helix and the hair crown. A square area of two centimeters by two centimeters was measured around the middle point of the hair crown (marked by a washable felt crayon). Photographs were taken of each participant's scalp.
  • The participants were seen at monthly intervals over a six-month period and their hair was analysed in the manner described above and photographs taken.
  • Results A. Treatment with Composition Comprising Finasteride, Latanoprost and Minoxidil
  • Each participant first had his hair analysed as described above and photographs taken. Following the first analysis, each participant was provided with a solution comprising 0.1% finasteride, 0.03% latanoprost and 5% minoxidil prepared as described in Example 1 above. The participants applied 1 ml to the scalp, once a day after cleansing. The 1 ml was applied as 10 metered dose sprays of 0.1 ml. The results for three participants are provided. Participant 1 was a male of 61 years of age (FIG. 1). Participant 2 was a male of 23 years of age (FIG. 2) while participant 3 was a male of 29 years of age (FIG. 3). All three participants had androgenetic alopecia, as did the participants of the comparator groups.
  • FIGS. 1, 2 and 3 clearly show a marked decrease of hair loss and an increase in hair regrowth in all three participants.
  • B. Comparison with Treatment with Minoxidil, Finasteride and Latanoprost Alone
  • Each participant first had his hair analysed as described in part A above and photographs taken. Following the first analysis, each participant was provided with a solution comprising either 5% minoxidil, 0.1% finasteride, or 0.03% latanoprost. The compositions were prepared as described in Examples 2 to 4 above. The participants applied 1 ml to the scalp, once a day after cleansing. The 1 ml was applied as 10 metered dose sprays of 0.1 ml.
  • The results for the participants of each group are provided.
  • The participant for the minoxidil group was a 64 year old male. FIG. 4 shows the results obtained for this participant. Only a slight improvement in hair regrowth is observed and the results are very inferior to those seen with the composition of the invention.
  • Four participants used a solution of 0.1% finasteride only. These participants were respectively 30 (participant 5), 33 (participant 6), 36 (participant 7) and 46 years of age (participant 8). FIGS. 5, 6, 7 and 8 show the results for participants 5, 6, 7 and 8 respectively.
  • Only a slight improvement in hair regrowth is observed. The results are far inferior to those seen with the composition of the invention.
  • Two participants used a solution comprising 0.03% latanoprost only. These participants were respectively 48 (participant 9) and 52 (participant 10) years of age. FIGS. 9 and 10 show the results for participants 9 and 10 respectively. Only a slight improvement in hair regrowth was observed. The results obtained are far inferior to those observed with the composition of the invention. The composition comprising minoxidil, finasteride and latanoprost shows improved properties in terms of reduction of hair loss and increase of regrowth of hair when compared to a solution of 5% minoxidil alone, a solution of 0.1% finasteride alone or a solution of 0.03% latanoprost alone. The improvements shown in the reduction of hair loss and the increase of regrowth hair for the composition of the invention are superior to the improvements seen for each of the components of the composition taken individually and the results obtained to date suggest that the improvements may be superior to those of the sum of the said components.
  • While the composition of the invention has been tested on males, similar results are expected on females as the mechanism of hair growth is the same for both genders.
  • While the present invention has been described in connection with specific embodiments thereof and in a specific use, various modifications will occur to those skilled in the art. The scope of the claims should not be limited by the preferred embodiments or the examples but should be given the broadest interpretation consistent with the description as a whole.

Claims (20)

1. A composition comprising 2% to 5% minoxidil, 0.01% to 15% finasteride and 0.01% to 15% of a prostaglandin analogue.
2. The composition according to claim 1 comprising 5% minoxidil, 0.5% finasteride and 0.1% of a prostaglandin analogue.
3. The composition according to claim 1 comprising 5% minoxidil, 0.1% finasteride and 0.03% of a prostaglandin analogue.
4. The composition according to claim 1, wherein the prostaglandin analogue is latanoprost, travoprost, bimatoprost, tafluprost or unoprostone.
5. The composition according to claim 4, wherein the prostaglandin analogue is latanoprost.
6. A composition comprising 5% minoxidil, 0.1% finasteride and 0.03% latanoprost.
7. The composition according to claim 1 for use in reducing hair loss; in increasing regrowth of hair; or in reducing hair loss and increasing regrowth of hair in a human subject.
8. The composition of claim 7, wherein the human subject is a male.
9. The composition of claim 7, wherein the human subject is a female.
10. The composition according to claim 1 for topical administration.
11. The composition according to claim 10 which is in the form of a spray.
12. Use of the composition as defined in claim 1 to reduce hair loss; increase regrowth of hair; or reduce hair loss and increase regrowth of hair in a human subject.
13. Use of the composition as defined in claim 1 in the manufacture of a medicament to reduce hair loss; increase regrowth of hair; or reduce hair loss and increase regrowth of hair in a human subject.
14. The use according to claim 12, wherein the human subject is a male.
15. The use according to claim 12, wherein the human subject is a female.
16. The use according to claim 12, wherein the composition is for topical administration.
17. The use according to claim 16, wherein the composition is in the form of a spray.
18. The use according to claim 13, wherein the human subject is a male.
19. The use according to claim13 wherein the human subject is a female.
20. The use according to claim 13, wherein the composition is for topical administration.
US15/292,819 2014-05-23 2016-10-13 Compositions for Reducing Hair Loss and/or Increasing Hair Regrowth Abandoned US20170100319A1 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
US201462002397P true 2014-05-23 2014-05-23
CA2903734 2015-05-22
PCT/CA2015/000327 WO2015176161A1 (en) 2014-05-23 2015-05-22 Compositions for reducing hair loss and/or increasing hair regrowth
CA2903734A CA2903734C (en) 2014-05-23 2015-05-22 Compositions for reducing hair loss and/or increasing hair regrowth
US201614917501A true 2016-03-08 2016-03-08
US15/292,819 US20170100319A1 (en) 2014-05-23 2016-10-13 Compositions for Reducing Hair Loss and/or Increasing Hair Regrowth

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15/292,819 US20170100319A1 (en) 2014-05-23 2016-10-13 Compositions for Reducing Hair Loss and/or Increasing Hair Regrowth

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
US14/917,501 Continuation US10470992B2 (en) 2014-05-23 2015-05-22 Compositions for reducing hair loss and/or increasing hair regrowth
PCT/CA2015/000327 Continuation WO2015176161A1 (en) 2014-05-23 2015-05-22 Compositions for reducing hair loss and/or increasing hair regrowth

Publications (1)

Publication Number Publication Date
US20170100319A1 true US20170100319A1 (en) 2017-04-13

Family

ID=54553133

Family Applications (2)

Application Number Title Priority Date Filing Date
US14/917,501 Active 2035-08-12 US10470992B2 (en) 2014-05-23 2015-05-22 Compositions for reducing hair loss and/or increasing hair regrowth
US15/292,819 Abandoned US20170100319A1 (en) 2014-05-23 2016-10-13 Compositions for Reducing Hair Loss and/or Increasing Hair Regrowth

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US14/917,501 Active 2035-08-12 US10470992B2 (en) 2014-05-23 2015-05-22 Compositions for reducing hair loss and/or increasing hair regrowth

Country Status (7)

Country Link
US (2) US10470992B2 (en)
EP (1) EP3062797B1 (en)
CN (2) CN109248167A (en)
CA (1) CA2903734C (en)
ES (1) ES2754353T3 (en)
PL (1) PL3062797T3 (en)
WO (1) WO2015176161A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10470992B2 (en) 2014-05-23 2019-11-12 Triple Hair Inc. Compositions for reducing hair loss and/or increasing hair regrowth

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3494955T3 (en) * 2017-12-08 2021-05-03 Escilab Spolka Z Ograniczona Odpowiedzialnoscia Cosmetic product for promoting hair growth
WO2021026084A1 (en) * 2019-08-07 2021-02-11 Aneira Pharma, Inc. Compositions for the treatment of hair loss

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100048598A1 (en) * 2008-08-21 2010-02-25 Sateesh Kandavilli Topical compositions comprising 5-alpha reductase inhibitors
WO2013078259A2 (en) * 2011-11-25 2013-05-30 Jackson Adrianna Janell Oil compositions and methods for increasing hair growth and/or preventing hair loss

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4746674A (en) 1985-08-27 1988-05-24 Cellena (Cell Engineering) Ag Melatonin compositions and uses thereof
US5407944A (en) 1993-02-19 1995-04-18 Goldman; Boris E. Compositions and methods for promoting hair growth
DE19509354A1 (en) 1994-12-08 1996-06-13 Klett Loch Lore M Combination preparation for promoting hair growth and possibly skin and nail growth and for preventing or eliminating hair loss
AUPN814496A0 (en) 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer
US6030948A (en) 1997-12-19 2000-02-29 Mann; Morris A. Hair regeneration compositions for treatment of alopecia and methods of application related thereto
US6284234B1 (en) 1998-08-04 2001-09-04 Johnson & Johnson Consumer Companies, Inc. Topical delivery systems for active agents
AU3596900A (en) 1999-02-19 2000-09-04 Marcus R. Jones Method and composition for promoting hair growth
US6495498B2 (en) 1999-05-27 2002-12-17 Johnson & Johnson Consumer Companies, Inc. Detergent compositions with enhanced depositing, conditioning and softness capabilities
CA2309373A1 (en) 1999-05-27 2000-11-27 Johnson & Johnson Consumer Companies, Inc. Novel topical formulations
DE19957710A1 (en) 1999-11-30 2001-05-31 Asat Ag Applied Science & Tech Treating female type androgenetic or diffuse alopecia by topical administration of melatonin, causing e.g. reduction of telogen rate and increase of anagen rate, hair diameter and tensile strength
US6828458B2 (en) 2000-05-25 2004-12-07 Biophysica, Inc. Topical antiandrogen for hair loss and other hyperandrogenic conditions
US20030199590A1 (en) 2002-07-25 2003-10-23 Cagle Gerald D Prostaglandin analogues for promotion of hair growth
US8758733B2 (en) 2002-02-04 2014-06-24 Allergan, Inc. Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists
US20060035924A1 (en) 2002-10-30 2006-02-16 Asat Ag Applied Science & Technology Daily melatonin dosing units
US20050003024A1 (en) 2003-03-04 2005-01-06 The Procter & Gamble Company Regulation of mammalian hair growth
ES2702607T3 (en) 2004-01-07 2019-03-04 E L Man Corporation Cosmetic composition and hair growth retardation method
JP2007526297A (en) 2004-03-02 2007-09-13 ジュリアーニ ソシエタ ペル アチオニ Compositions for modulating hair follicle tropism and sebum skin formation and their use in androgenic alopecia
US7834210B2 (en) 2006-08-04 2010-11-16 Bioderm Research Hair loss prevention by natural amino acid and peptide complexes
US20080095866A1 (en) 2004-09-14 2008-04-24 Ajinomoto Omnichem S.A. Topical Compositions Containing Phosphorylated Polyphenols
EP1726292A1 (en) 2005-05-23 2006-11-29 Reckitt Benckiser (UK) LIMITED Composition comprising resveratrol and topical use thereof for reducing human hair growth
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
ITRM20060108A1 (en) 2006-03-03 2007-09-04 Colella Gino MELATONIN-BASED COMPOSITIONS AND IMMUNOSTIMULATING SUBSTANCES
US7704533B2 (en) 2006-12-13 2010-04-27 J&J Consumer Companies, Inc. Compositions and methods of inducing hair growth utilizing Continus coggygria
AR068409A1 (en) 2007-09-14 2009-11-18 Drugtech Corp Pharmaceutical compositions, transdermal without alcohol
EP2153836A1 (en) 2008-08-04 2010-02-17 Polichem S.A. Film-forming liquid formulations for drug release to hair and scalp
JP2010258094A (en) 2009-04-22 2010-11-11 Panasonic Corp Solid-state imaging device
GB2471135A (en) 2009-06-19 2010-12-22 H D S Ltd Hair dye composition and use in reducing contact allergy
WO2011031990A1 (en) 2009-09-11 2011-03-17 Follica, Inc. Intermittent and pulse lithium treatments for modulating hair growth
US8470833B2 (en) 2009-12-15 2013-06-25 Mcneil-Ppc, Inc. Hair growth and/or regrowth compositions
US8470880B2 (en) 2009-12-15 2013-06-25 Mcneil-Ppc, Inc. Methods of reducing hair loss and/or facilitating hair growth and/or regrowth
GB2477913A (en) 2010-02-11 2011-08-24 Pangaea Lab Ltd A hair building solid agent with electrostatic effects
WO2012078649A1 (en) 2010-12-06 2012-06-14 Follica, Inc. Methods for treating baldness and promoting hair growth
CA2834262C (en) 2011-04-28 2020-08-25 Borje S. Andersson Improved parenteral formulations of lipophilic pharmaceutical agents and methods for preparing and using the same
WO2013142295A1 (en) * 2012-03-21 2013-09-26 The Trustees Of The University Of Pennsylvania Compositions and methods for regulating hair growth
WO2013181487A2 (en) 2012-05-31 2013-12-05 Stiefel Laboratories, Inc. Method of treating
US20160346183A1 (en) 2014-05-23 2016-12-01 Triple Hair, Inc. Compositions for Reducing Hair Loss And/Or Increasing Hair Regrowth
CA2903734C (en) 2014-05-23 2016-03-01 Houfar SEKHAVAT Compositions for reducing hair loss and/or increasing hair regrowth

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100048598A1 (en) * 2008-08-21 2010-02-25 Sateesh Kandavilli Topical compositions comprising 5-alpha reductase inhibitors
WO2013078259A2 (en) * 2011-11-25 2013-05-30 Jackson Adrianna Janell Oil compositions and methods for increasing hair growth and/or preventing hair loss

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10470992B2 (en) 2014-05-23 2019-11-12 Triple Hair Inc. Compositions for reducing hair loss and/or increasing hair regrowth

Also Published As

Publication number Publication date
CA2903734C (en) 2016-03-01
US20160213590A1 (en) 2016-07-28
CN109248167A (en) 2019-01-22
CN105658223A (en) 2016-06-08
CA2903734A1 (en) 2015-11-23
ES2754353T3 (en) 2020-04-17
CN105658223B (en) 2018-12-04
EP3062797A1 (en) 2016-09-07
US10470992B2 (en) 2019-11-12
WO2015176161A1 (en) 2015-11-26
EP3062797B1 (en) 2019-08-28
PL3062797T3 (en) 2020-08-24
EP3062797A4 (en) 2016-11-23

Similar Documents

Publication Publication Date Title
US20170100319A1 (en) Compositions for Reducing Hair Loss and/or Increasing Hair Regrowth
US20160228345A1 (en) Compositions and methods for hair growth
US20070264317A1 (en) Imiquimod cream formulation
US20160346183A1 (en) Compositions for Reducing Hair Loss And/Or Increasing Hair Regrowth
US20110112198A1 (en) Compositions for enhancing hair growth
US20150164765A1 (en) Compositions and methods for hair growth
US10610509B2 (en) Combinations of prostaglandins and nitric oxide donors
US10016351B2 (en) Composition for promoting hair growth or preventing hair loss
US10363258B2 (en) Treatment of migraines
US20150190322A1 (en) Composition, method and kit for enhancing hair
US6288112B1 (en) Use of pyrethroid compounds to promote hair growth
US8859616B2 (en) Compounds and methods for enhancing hair growth
EP2600825B1 (en) Method for curling hair
US20190183890A1 (en) Methods and compositions for promoting hair growth
US20160128926A1 (en) Compositions and methods for treating nails, claws, and hoofs
WO2020263115A1 (en) Agent for promoting hair growth

Legal Events

Date Code Title Description
AS Assignment

Owner name: TRIPLE HAIR INC., CANADA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SEKHAVAT, HOUFAR;REEL/FRAME:040978/0224

Effective date: 20160411

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STCV Information on status: appeal procedure

Free format text: NOTICE OF APPEAL FILED

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION